Efficacy of trametinib in a metastatic urothelial carcinoma patient with a BRAF mutation

Hiroyuki Karasawa; Yota Yasumizu; Takeo Kosaka; Tatsunori Shimoi; Mototsugu Oya

doi:10.1002/iju5.12759

Efficacy of trametinib in a metastatic urothelial carcinoma patient with a BRAF mutation

Hiroyuki Karasawa, Yota Yasumizu, Takeo Kosaka, Tatsunori Shimoi, Mototsugu Oya

Department of Urology

Research output: Contribution to journal › Article › peer-review

Abstract

Introduction: BRAF mutations in bladder cancer are rare. MEK inhibitors have excellent clinical benefits in the treatment of melanoma. Case presentation: A 60-year-old male was diagnosed with muscle-invasive bladder cancer and underwent total cystectomy and ileal conduit diversion. Despite 4 cycles of gemcitabine and cisplatin chemotherapy and 3 courses of pembrolizumab, the left obturator lymph node enlarged. Cancer multi-gene panel testing confirmed the BRAF G469A mutation and trametinib was recommended. Three months after the initiation of trametinib (2 mg, qd), the left obturator lymph node shrank by more than 50%. The disease has remained stable for more than 18 months. Conclusion: The present case indicates the potential of trametinib to treat mBUC patients with the BRAF G469A mutation in this setting.

Original language	English
Pages (from-to)	375-378
Number of pages	4
Journal	IJU Case Reports
Volume	7
Issue number	5
DOIs	https://doi.org/10.1002/iju5.12759
Publication status	Published - 2024 Sept

Keywords

BRAF G469A
MEK inhibitor
patient-proposed healthcare services
urothelial carcinoma

ASJC Scopus subject areas

Urology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/iju5.12759

Cite this

@article{db37770be2ca445bae8e85d207547535,

title = "Efficacy of trametinib in a metastatic urothelial carcinoma patient with a BRAF mutation",

abstract = "Introduction: BRAF mutations in bladder cancer are rare. MEK inhibitors have excellent clinical benefits in the treatment of melanoma. Case presentation: A 60-year-old male was diagnosed with muscle-invasive bladder cancer and underwent total cystectomy and ileal conduit diversion. Despite 4 cycles of gemcitabine and cisplatin chemotherapy and 3 courses of pembrolizumab, the left obturator lymph node enlarged. Cancer multi-gene panel testing confirmed the BRAF G469A mutation and trametinib was recommended. Three months after the initiation of trametinib (2 mg, qd), the left obturator lymph node shrank by more than 50%. The disease has remained stable for more than 18 months. Conclusion: The present case indicates the potential of trametinib to treat mBUC patients with the BRAF G469A mutation in this setting.",

keywords = "BRAF G469A, MEK inhibitor, patient-proposed healthcare services, urothelial carcinoma",

author = "Hiroyuki Karasawa and Yota Yasumizu and Takeo Kosaka and Tatsunori Shimoi and Mototsugu Oya",

note = "Publisher Copyright: {\textcopyright} 2024 The Author(s). IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of Japanese Urological Association.",

year = "2024",

month = sep,

doi = "10.1002/iju5.12759",

language = "English",

volume = "7",

pages = "375--378",

journal = "IJU Case Reports",

issn = "2577-171X",

publisher = "John Wiley and Sons Inc.",

number = "5",

}

TY - JOUR

T1 - Efficacy of trametinib in a metastatic urothelial carcinoma patient with a BRAF mutation

AU - Karasawa, Hiroyuki

AU - Yasumizu, Yota

AU - Kosaka, Takeo

AU - Shimoi, Tatsunori

AU - Oya, Mototsugu

PY - 2024/9

Y1 - 2024/9

N2 - Introduction: BRAF mutations in bladder cancer are rare. MEK inhibitors have excellent clinical benefits in the treatment of melanoma. Case presentation: A 60-year-old male was diagnosed with muscle-invasive bladder cancer and underwent total cystectomy and ileal conduit diversion. Despite 4 cycles of gemcitabine and cisplatin chemotherapy and 3 courses of pembrolizumab, the left obturator lymph node enlarged. Cancer multi-gene panel testing confirmed the BRAF G469A mutation and trametinib was recommended. Three months after the initiation of trametinib (2 mg, qd), the left obturator lymph node shrank by more than 50%. The disease has remained stable for more than 18 months. Conclusion: The present case indicates the potential of trametinib to treat mBUC patients with the BRAF G469A mutation in this setting.

AB - Introduction: BRAF mutations in bladder cancer are rare. MEK inhibitors have excellent clinical benefits in the treatment of melanoma. Case presentation: A 60-year-old male was diagnosed with muscle-invasive bladder cancer and underwent total cystectomy and ileal conduit diversion. Despite 4 cycles of gemcitabine and cisplatin chemotherapy and 3 courses of pembrolizumab, the left obturator lymph node enlarged. Cancer multi-gene panel testing confirmed the BRAF G469A mutation and trametinib was recommended. Three months after the initiation of trametinib (2 mg, qd), the left obturator lymph node shrank by more than 50%. The disease has remained stable for more than 18 months. Conclusion: The present case indicates the potential of trametinib to treat mBUC patients with the BRAF G469A mutation in this setting.

KW - BRAF G469A

KW - MEK inhibitor

KW - patient-proposed healthcare services

KW - urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85198097862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85198097862&partnerID=8YFLogxK

U2 - 10.1002/iju5.12759

DO - 10.1002/iju5.12759

M3 - Article

AN - SCOPUS:85198097862

SN - 2577-171X

VL - 7

SP - 375

EP - 378

JO - IJU Case Reports

JF - IJU Case Reports

IS - 5

ER -

Efficacy of trametinib in a metastatic urothelial carcinoma patient with a BRAF mutation

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this